Trest

Quick links to important sections

Trest

Treatment option: Pain, Chronic Pain

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Trest

Understanding Trest

Trest is a synthetic androgen and anabolic steroid. It is a derivative of nandrolone and is characterized by its significant potency in binding to androgen receptors. Unlike some other synthetic hormones, it is also capable of interacting with estrogen receptors through a process called aromatization.

Mechanism of Action

The compound works by mimicking the effects of naturally occurring testosterone in the body. It binds to androgen receptors in various tissues, including muscle and bone, to promote growth and maintenance. Because of its unique chemical structure, it is often studied for its ability to maintain physiological functions that typically require both androgens and estrogens, such as bone density and libido, even when natural testosterone production is suppressed.

Historical Context and Research

Initially developed for potential use in hormone replacement therapy and male contraception, research has focused on its efficacy in supporting secondary male characteristics and muscle mass. In clinical research settings, it has been evaluated for its potential to provide a balanced hormonal profile without the need for supplemental medications to manage estrogenic activity.

Physical Properties

As a 19-nortestosterone derivative, it exhibits a high affinity for the androgen receptor, making it significantly more potent than standard testosterone. Its chemical modifications allow it to resist certain metabolic pathways, which contributes to its biological activity and the specific way it is processed by the liver and other tissues.

What side effects are possible with Trest?

Possible Side Effects and Safety Information

The official safety profile of Trest (Tramadol Hydrochloride) is categorized by government regulatory bodies based on documented frequency and impact on body systems. The medicine's risk profile includes highly frequent, non-serious reactions alongside rare but critical risks, ensuring comprehensive communication of safety data.

Frequency-Classified Adverse Reactions

Adverse reactions are formally grouped by how often they occur in clinical use:

  • Very Common (Affecting ge 1/10): Nausea, Dizziness, Somnolence.
  • Common (Affecting ge 1/100 to < 1/10): Vomiting, Constipation, Sweating (Hyperhidrosis), Dry mouth, Headache, Fatigue.
  • Uncommon (Affecting ge 1/1,000 to < 1/100): Cardiovascular effects (e.g., Palpitations, Tachycardia), Gastrointestinal irritation, Dermatological reactions.

Most reported adverse reactions primarily affect the Nervous System and Gastrointestinal System. Regulatory documents note that effects such as nausea and dizziness are often more prevalent at the beginning of treatment or following an increase in dose.

Serious Adverse Reactions and Safety Constraints

Certain reactions are highlighted in regulatory labeling as serious safety concerns:

  • Serious Risks: These include Respiratory Depression, Seizures, and Serotonin Syndrome. These events, though rare, are highlighted with specific regulatory warnings.
  • Long-Term Exposure Risks: Chronic use of Trest is associated with the risks of developing tolerance, physical dependence, and Adrenal Insufficiency.
  • Population Constraints: Safety constraints are documented for specific groups, including Older Adults (aged over 75) and patients with Renal or Hepatic Impairment, due to documented increased systemic exposure and subsequent risk of side effects. The use of Trest is further restricted in pediatric patients under 12 years of age and in certain adolescents.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Trest (Tramadol Hydrochloride) is officially documented as a potentially life-threatening emergency that requires immediate medical attention. The official regulatory labeling specifies acute overdose manifests primarily as severe Central Nervous System (CNS) depression and respiratory depression.

Documented Overdose Signs Severe Outcomes Mandated to Require Help
Miosis (pinpoint pupils) Respiratory arrest and fatal outcome
Seizures (Convulsions) Coma and Cardiovascular collapse
Severe Somnolence Serotonin Syndrome risk (with co-ingestion)

Regulatory authorities explicitly mandate that any sign of suspected overdose, including severe drowsiness or breathing difficulty, requires you to seek immediate medical attention or contact emergency services.

Management in a medical setting focuses on symptomatic and supportive care. Naloxone may be administered to reverse life-threatening respiratory depression; however, official guidance notes it may not fully reverse all toxic effects, such as seizures. Procedures like gastric lavage and activated charcoal are described methods for decontamination if performed soon after acute ingestion. Continuous monitoring of respiratory and cardiovascular status is required, and overdose severity may be increased in patients with hepatic or renal impairment.

Therapeutic Uses of Trest

What Trest treats: main uses and benefits

Trest is commonly used to help manage symptoms of pain that are categorized as moderate-to-severe, generally in situations where alternative treatments are inadequate. This is relevant within the context of therapeutic areas where additional symptomatic support is needed. The medication is commonly used to help with acute painful episodes, such as the discomfort experienced following surgical procedures or a significant traumatic injury, as well as in managing symptoms of chronic pain conditions, including persistent pain associated with advanced osteoarthritis and certain recurrent musculoskeletal and neuropathic manifestations.


Key Therapeutic Contexts

The medication assists with symptomatic relief in conditions presenting with significant discomfort. It is commonly applied in scenarios where patients experience heightened distress, particularly after surgery or trauma, or during phases of intensified pain from chronic disease. In all these contexts, Trest may assist with symptom clusters that interfere with daily functioning, offering supportive relief that helps patients cope more steadily.

“Trest is commonly used to help patients cope more steadily with symptom fluctuations and contributes to easing the overall symptom load.”

Quick Fact: Relief for Pain that Interferes with Daily Function

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Trest — Official Regulatory Information

Official regulatory documents define strict criteria for using Trest (Tramadol Hydrochloride), categorizing who is eligible, who requires special caution, and who must not use the medicine.

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) [Source 1.2]. Adolescents 12 years of age and older (with exceptions) [Source 1.3].
Populations for whom use is contraindicated Children younger than 12 years of age [Source 1.4]. Children younger than 18 years of age following tonsillectomy and/or adenoidectomy [Source 1.4]. Patients with significant respiratory depression, acute asthma, or uncontrolled epilepsy [Source 1.4, 2.3]. Patients using MAOIs or who have used them within the last 14 days [Source 1.4]. Patients in a state of acute intoxication (alcohol, hypnotics, opioids) [Source 2.3].
Condition-specific limitations Use is not recommended in patients with severe renal or hepatic impairment due to the accumulation of the drug and its active metabolite [Source 2.3]. Avoid use in adolescents (12–18 years) with risk factors for breathing problems, such as sleep apnea or obesity [Source 1.4].
Reproductive eligibility status Pregnancy: Prolonged use is linked to neonatal opioid withdrawal syndrome [Source 1.4]. Lactation: Use is not recommended during breastfeeding due to the risk of serious adverse reactions in the infant [Source 2.1].

These official statements define who can be considered for Trest and exclude non-eligible groups based strictly on regulatory classification, patient age, comorbidities, and physiological status.

What should I know about interactions with other medicines?

Trest Interactions with other medicines and products

The interaction profile for Trest (Tramadol Hydrochloride) is defined by its metabolic clearance and its activity within the central nervous system. Officially documented interactions involve both pharmacokinetic (metabolism-based) and pharmacodynamic (additive-effect) mechanisms, as stated in regulatory labels.


Key Regulatory Restrictions

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated and prohibited within 14 days of discontinuing an MAOI. Additionally, concomitant consumption of alcohol-containing beverages is restricted due to the enhanced risk of severe central nervous system (CNS) depression and life-threatening respiratory effects.


Pharmacokinetic and Pharmacodynamic Interactions

Exposure Modification: Trest is metabolized by CYP2D6 and CYP3A4 enzymes. Co-administration with enzyme inhibitors (e.g., specific antidepressants, antifungals) may increase plasma concentrations of Trest, while enzyme inducers (e.g., Carbamazepine) may lead to a reduced analgesic effect. Pharmacodynamic Reinforcement occurs with other CNS Depressants or Serotonergic Drugs (e.g., SSRIs, triptans), increasing the risk of profound sedation or Serotonin Syndrome. Interactions with Warfarin have been documented, noting an alteration of the anticoagulant effect, including elevated prothrombin times. Furthermore, individuals classified as CYP2D6 ultra-rapid metabolizers are noted to have a heightened risk of toxicity due to rapid conversion to the active M1 metabolite.

Mechanism of Action

Trest (tranexamic acid) is an antifibrinolytic agent that modulates key components of the blood clotting and breakdown system. Its mechanism involves regulating overactive or dysregulated processes in the body's natural clot-dissolving pathway, resulting in pathway-level modifications.


Enzyme Inhibition in the Fibrinolytic Pathway

Trest primarily exerts its action by competitively inhibiting the activation of the protein plasminogen to its active form, plasmin. Plasmin is the key enzyme responsible for the degradation of fibrin, the structural mesh that stabilizes a blood clot. Trest binds to specific sites on the plasminogen molecule, preventing its effective engagement with the fibrin surface. This direct interaction modifies early molecular steps in the fibrinolytic cascade, leading to the system-level physiological consequence of reducing the rate of fibrinolysis.


Modulating Mediators of Vascular Permeability

At higher concentrations, Trest also engages mechanisms that influence non-clotting systems. It modulates pathways governed by mediators that influence vascular permeability. This secondary action contributes to a more regulated state within targeted tissue pathways, influencing systemic responses.

Dosage and Administration Information

How to use Trest

Trest is administered either orally as tablets, capsules, or an oral solution, or via the parenteral route as an injection solution. The medicine is primarily available in two main formulations: Immediate-Release (IR) and Extended-Release (ER), and this distinction strictly governs the dosing schedule. The IR form is used on an as-needed basis (PRN), with doses typically taken every four to six hours, and the daily dose must not exceed 400 mg. The ER form, however, is designed for once-daily, scheduled use and is not indicated for as-needed treatment, with the maximum daily dose limited to 300 mg.

Dosing for IR formulations can begin as low as 25 mg daily, followed by slow titration. Administration can occur without regard to food for oral formulations. A crucial administration restriction is that all Extended-Release tablets and capsules must be swallowed whole and must not be crushed, split, or dissolved to preserve the integrity of the controlled-release mechanism.

Specific adjustments to the standard regimen are mandated for certain patient populations to maintain appropriate systemic exposure. For adults over 75 years of age, the total daily dose of the IR formulation is restricted to 300 mg. Patients with severe impairment of kidney or liver function require a significantly modified schedule, often involving extended 12-hour dosing intervals and a reduction in the maximum daily dose. The Extended-Release formulations are not recommended for use in individuals with severe renal or hepatic impairment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Trest


Evidence for use in Relieving Migraine Headache Pain

This section summarizes the research that has explored Trest’s use for outcomes related to acute migraine headaches. Trest was evaluated in short-term clinical trials focusing on conditions characterized by fluctuating or episodic manifestations, with the goal of observing outcomes describing episodic or acute changes related to physical discomfort. Research in this area involves studies where responses were monitored over defined time intervals following the onset of a headache.

The findings describe patterns observed in the studies related to a change in patient-reported outcomes describing perceived discomfort during a migraine episode. Research highlights changes measured during the study period in outcomes related to physical discomfort. These studies contribute to the broader evidence landscape by providing data on observed symptom patterns in the study populations.


Evidence for use in Preventing Episodic Migraine Headaches

Research has also explored the potential role of Trest in conditions involving periods of heightened symptoms, specifically assessing outcomes related to systemic or functional imbalance over longer treatment periods. These trials focused on outcomes reflecting daily functioning or activity level, such as the change in the frequency of days with migraine headaches.

Data show patterns related to a change in the number of days with migraine for some individuals observed in the studies. Research provides insight into short-term changes in these outcomes, particularly within the first few months of use.


Long-term studies and follow-up

Research has also examined the patterns observed when individuals continue to use Trest beyond the initial, shorter trial duration. Follow-up data from extension studies contribute to the broader evidence landscape by providing information on patterns observed over longer timeframes.

Despite this, long-term effects are not fully established regarding the durability of the observed changes on conditions where symptoms may vary in intensity. Research is ongoing to track outcomes for patients over more extended periods.


What is still uncertain about Trest

Evidence highlights what is known—and what is still uncertain. A key area of uncertainty is that research does not determine whether an individual will respond similarly, as findings describe group patterns, not personal outcomes. Evidence is limited in determining the exact individual characteristics that predict whether Trest appears to be associated with a change in outcomes. Comparative evidence is lacking, making it difficult to compare findings with all other available treatments.

Frequently Asked Questions (FAQ)

Common questions about Trest (FAQ)

Q: How long does it typically take to feel the effects of Trest?

A: According to the official product information, patients taking the immediate-release (IR) oral formulation typically begin to feel pain relief within one hour of taking the medicine. The peak effect, where the medicine is working most powerfully, usually occurs within two to three hours after administration.

Q: What research studies are available for Trest?

A: Official regulatory documents include summaries of the controlled clinical trials and studies used to establish Trest's safety and effectiveness. These studies provide data on its approved use for the management of pain, as reported to government health authorities.

Q: Can Trest be used by older adults?

A: Yes, Trest can be used by older adults. However, regulatory guidelines note that specific dose adjustments may be necessary for patients over 75 years of age due to potential changes in metabolism and elimination. This is a consideration included in the official prescribing information.

Q: Can Trest be crushed or opened if I have trouble swallowing pills?

A: Official instructions state that Extended-Release (ER) formulations must be swallowed whole and must never be crushed, split, or chewed, as altering the ER formulation can lead to a dangerously high dose being released too quickly. If there is difficulty swallowing pills, consulting a healthcare professional is necessary to determine the appropriate alternative formulation or administration method.

Q: What is the difference between Trest and standard testosterone therapy?

A: Trest's active ingredient, Tramadol Hydrochloride, is a synthetic, centrally-acting opioid analgesic used to treat pain. It works by affecting specific receptors and chemical messengers in the central nervous system. It is not a hormone and is chemically and functionally distinct from testosterone therapy.

Q: What is Trest used for outside of traditional hormone therapy?

A: The approved therapeutic purpose of Trest (Tramadol Hydrochloride), according to regulatory documents, is the management of moderate-to-severe pain in adults.

Q: Is the onset of Trest's effects immediate or gradual?

A: For immediate-release formulations, the onset of pain relief is generally considered gradual, beginning approximately within one hour after administration.

Q: What should I do if I miss a scheduled time to take Trest?

A: Patient information generally advises against taking two doses at once to make up for a missed dose. If a dose is missed, taking the next one at the regularly scheduled time is often advised. Specific guidance on missed doses should be obtained from a healthcare provider.

Q: What are the signs that Trest is starting to work for me?

A: Trest is indicated for pain management. Therefore, the primary sign that the medicine is working would be a reduction in the severity of pain or an overall improvement in pain-related symptoms.

Q: Can I take Trest if I have a history of liver issues?

A: Trest should be used with caution in patients with impaired liver function. The medicine is primarily metabolized by the liver, and severe impairment requires specific dosage adjustments to prevent the medicine from accumulating in the body.

Q: What kind of monitoring or tests are needed while on Trest?

A: Regulatory documents advise routine re-evaluation of the continued need for Trest treatment, especially during long-term use. Furthermore, regulatory documents indicate that monitoring for signs of serious effects, such as respiratory depression and changes in mental status, is part of safe management.

Q: Are there any dietary restrictions I should know about while using Trest?

A: Official warnings highlight that consuming alcohol while taking Trest is restricted. This is because combining the two significantly enhances the risk of severe central nervous system (CNS) depression and life-threatening respiratory effects.

Q: Is it better to take Trest in the morning or at night?

A: The timing for taking Trest depends on the specific formulation (extended-release or immediate-release) and the patient's individual pain needs. The timing for oral formulations is generally stated to be without regard to food.

Q: What happens if I stop taking Trest suddenly?

A: Abrupt discontinuation can lead to withdrawal symptoms, which may include anxiety, sweating, tremors, pain, nausea, and diarrhea. To reduce the risk of withdrawal, official guidance suggests that the dose should be gradually reduced, or tapered, over time.

Q: Is Trest known by any other names (generic or brand)?

A: The active ingredient in Trest is Tramadol Hydrochloride. This medicine is marketed under various brand names, including Ultram, Ultram ER, and Conzip.

Q: Are there any specific organs Trest puts a strain on?

A: The medicine is primarily processed by the liver and eliminated by the kidneys. Impairment of either of these organs can cause the drug and its active metabolite to build up in the body, which is why dose adjustments are required for patients with severe impairment.

Q: Are there any specific health conditions that make Trest use risky?

A: Trest is contraindicated or carries a high risk for individuals with conditions such as significant respiratory depression, acute or severe bronchial asthma, uncontrolled epilepsy, or those in a state of acute intoxication from other substances.

Q: Can women take Trest, or is it only for men?

A: Trest is approved for use in adults 18 years and older of both sexes for pain management. However, its use is generally not recommended during pregnancy or breastfeeding due to documented potential risks to the infant.

Q: Is Trest the same as 'Trestolone' or something different?

A: No, they are different. Trest refers to Tramadol Hydrochloride, a synthetic opioid analgesic. Trestolone, on the other hand, is an investigational anabolic steroid, meaning the two compounds have entirely different chemical structures and medical purposes.

Q: Will Trest show up on a standard drug test?

A: Trest's active ingredient, Tramadol, may not be detected on a standard 5- or 10-panel drug test. To detect Tramadol or its active metabolite (O-desmethyltramadol), a specific drug panel or an extended test ordered by a medical professional is typically required.

How should Trest be stored and disposed of?

Trest (Tramadol Hydrochloride) must be stored and handled strictly according to the official regulatory labeling.

Storage Conditions

Trest must be stored at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F), protected from moisture, excessive heat, and freezing. The medicine must remain in its original container and be kept tightly closed to maintain product stability. As an opioid analgesic, Trest must be stored in a secure place and kept out of the sight and reach of children to prevent fatal accidental ingestion.

Disposal Instructions

Do not throw away unused or expired Trest in household waste or flush it down the toilet. The product should be disposed of through a drug take-back program or as directed by a healthcare provider. If a take-back program is unavailable, officially documented guidance instructs mixing the medicine with an undesirable substance before sealing and discarding.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Trest found in:

A-Z Index: